Veterinary anaesthesia and analgesia · 2026
Effectiveness of dimenhydrinate and maropitant in preventing preoperative emesis and nausea in healthy dogs sedated with hydromorphone and dexmedetomidine: a randomized, blinded trial.
СтатьяRandomized Controlled Trial, VeterinaryНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shin Chi W, Ambros Barbara
Аннотация
OBJECTIVE: To determine the antinausea and antiemetic effects of dimenhydrinate and maropitant in dogs when administered 60 minutes before hydromorphone and dexmedetomidine.
STUDY DESIGN: Prospective, randomized, blinded, placebo-controlled clinical trial.
ANIMALS: A total of 87 healthy client-owned dogs undergoing ovariectomy/castration.
METHODS: Dogs were randomly assigned to be administered maropitant (1 mg kg-1; group M) subcutaneously (SC), dimenhydrinate (4 mg kg-1; group D) intramuscularly (IM), or 0.9% NaCl (0.1 mL kg-1; group C) SC 60 minutes before anesthetic premedication with hydromorphone (0.1 mg kg-1) and dexmedetomidine (5-15 μg kg-1) IM. Incidences of discomfort after injection of the treatment drug, nausea (ptyalism, lip licking, and swallowing), and vomiting/retching were documented. Scores for nausea and sedation were assigned immediately before premedication and for 20 minutes after premedication. Data were analyzed using Fisher's Exact test and Kruskal-Wallis test, with statistical significance set at p< 0.05.
RESULTS: Discomfort to injection was significantly higher in group M (20/31, 64.5%) than in groups D (6/28, 21.4%) and C (2/28, 7.1%) (p< 0.0001). Incidence of nausea was not significantly different between treatment groups [group M; 23/31 (74.2%) versus group D; 27/28 (96%) versus group C; 23/28 (82.1%), p= 0.050]. The incidence of vomiting/retching was significantly lower in group M (0/31, 0%) compared to groups D (15/28, 53.6%) and C (9/28, 32.1%) (p< 0.0001).
CONCLUSIONS AND CLINICAL RELEVANCE: Dimenhydrinate produced no measurable antinausea and antiemetic effect when administered 60 minutes before hydromorphone and dexmedetomidine. Maropitant SC prevented hydromorphone-induced emesis but was ineffective in reducing nausea.
STUDY DESIGN: Prospective, randomized, blinded, placebo-controlled clinical trial.
ANIMALS: A total of 87 healthy client-owned dogs undergoing ovariectomy/castration.
METHODS: Dogs were randomly assigned to be administered maropitant (1 mg kg-1; group M) subcutaneously (SC), dimenhydrinate (4 mg kg-1; group D) intramuscularly (IM), or 0.9% NaCl (0.1 mL kg-1; group C) SC 60 minutes before anesthetic premedication with hydromorphone (0.1 mg kg-1) and dexmedetomidine (5-15 μg kg-1) IM. Incidences of discomfort after injection of the treatment drug, nausea (ptyalism, lip licking, and swallowing), and vomiting/retching were documented. Scores for nausea and sedation were assigned immediately before premedication and for 20 minutes after premedication. Data were analyzed using Fisher's Exact test and Kruskal-Wallis test, with statistical significance set at p< 0.05.
RESULTS: Discomfort to injection was significantly higher in group M (20/31, 64.5%) than in groups D (6/28, 21.4%) and C (2/28, 7.1%) (p< 0.0001). Incidence of nausea was not significantly different between treatment groups [group M; 23/31 (74.2%) versus group D; 27/28 (96%) versus group C; 23/28 (82.1%), p= 0.050]. The incidence of vomiting/retching was significantly lower in group M (0/31, 0%) compared to groups D (15/28, 53.6%) and C (9/28, 32.1%) (p< 0.0001).
CONCLUSIONS AND CLINICAL RELEVANCE: Dimenhydrinate produced no measurable antinausea and antiemetic effect when administered 60 minutes before hydromorphone and dexmedetomidine. Maropitant SC prevented hydromorphone-induced emesis but was ineffective in reducing nausea.